- Home
- KTTA vs CNSP Comparison
KTTA vs CNSP Comparison
Compare KTTA & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- CNSP
- Stock Information
- Founded
- KTTA 2020
- CNSP 2017
- Country
- KTTA United States
- CNSP United States
- Employees
- KTTA N/A
- CNSP N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- CNSP Health Care
- Exchange
- KTTA Nasdaq
- CNSP Nasdaq
- Market Cap
- KTTA 5.1M
- CNSP 4.0M
- IPO Year
- KTTA 2021
- CNSP 2019
- Fundamental
- Price
- KTTA $0.68
- CNSP $6.70
- Analyst Decision
- KTTA
- CNSP Hold
- Analyst Count
- KTTA 0
- CNSP 1
- Target Price
- KTTA N/A
- CNSP N/A
- AVG Volume (30 Days)
- KTTA 119.6K
- CNSP 31.6K
- Earning Date
- KTTA 08-19-2025
- CNSP 08-18-2025
- Dividend Yield
- KTTA N/A
- CNSP N/A
- EPS Growth
- KTTA N/A
- CNSP N/A
- EPS
- KTTA N/A
- CNSP N/A
- Revenue
- KTTA N/A
- CNSP N/A
- Revenue This Year
- KTTA N/A
- CNSP N/A
- Revenue Next Year
- KTTA N/A
- CNSP N/A
- P/E Ratio
- KTTA N/A
- CNSP N/A
- Revenue Growth
- KTTA N/A
- CNSP N/A
- 52 Week Low
- KTTA $0.65
- CNSP $6.66
- 52 Week High
- KTTA $7.50
- CNSP $221.94
- Technical
- Relative Strength Index (RSI)
- KTTA 38.79
- CNSP 27.80
- Support Level
- KTTA $0.67
- CNSP $7.50
- Resistance Level
- KTTA $0.79
- CNSP $8.33
- Average True Range (ATR)
- KTTA 0.04
- CNSP 0.79
- MACD
- KTTA 0.00
- CNSP -0.09
- Stochastic Oscillator
- KTTA 23.70
- CNSP 1.49
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.